Halozyme Therapeutics Inc (NASDAQ: HALO) has benefited from exceptional positive changes in investment behavior: the stock rose on very heavy volume, and positive upside/downside volume developed.
Halozyme Therapeutics Inc (NASDAQ: HALO) has benefited from important positive changes in fundamentals: significant quarterly earnings acceleration occurred, and the consensus estimate for December, 2026 increased significantly.
In light of these very positive signals we are reviewing our current Overall Rating of A. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
Halozyme Therapeutics has a current Value Trend Rating of A (Highest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing complementary signals. Halozyme Therapeutics has a slightly positive Power Rating of 65 and a very high Appreciation Score of 97, leading to the Highest Value Trend Rating.
Recent Price Action
On 9/19/25, Halozyme Therapeutics Inc (NASDAQ: HALO) stock increased 1.5%, closing at $77.81. Moreover, exceptionally high trading volume at 332% of normal accompanied the advance. The stock has been strong relative to the market over the last nine months and is unchanged during the last week.
Be the first to comment